1887

Abstract

The array of human immunodeficiency virus (HIV) subtypes encountered in East London, an area long associated with migration, is unusually heterogeneous, reflecting the diverse geographical origins of the population. In this study it was shown that viral subtypes or clades infecting a sample of HIV type 1 (HIV-1)-positive individuals in East London reflect the global pandemic. The authors studied the humoral response in 210 treatment-naïve chronically HIV-1-infected (>1 year) adult subjects against a panel of 12 viruses from six different clades. Plasmas from individuals infected with clade C, but also plasmas from clade A, and to a lesser degree clade CRF02_AG and CRF01_AE, were significantly more potent at neutralizing the tested viruses compared with plasmas from individuals infected with clade B. The difference in humoral robustness between clade C- and B-infected patients was confirmed in titration studies with an extended panel of clade B and C viruses. These results support the approach to develop an HIV-1 vaccine that includes clade C or A envelope protein (Env) immunogens for the induction of a potent neutralizing humoral response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.024224-0
2010-11-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/11/2794.html?itemId=/content/journal/jgv/10.1099/vir.0.024224-0&mimeType=html&fmt=ahah

References

  1. Aasa-Chapman, M., Hayman, A., Newton, P., Cornforth, D., Williams, I., Borrow, P., Balfe, P. & McKnight, A. ( 2004; ). Development of the antibody response in acute HIV-1 infection. AIDS 18, 371–381.[CrossRef]
    [Google Scholar]
  2. Arora, P., Kumar, R., Bhattacharya, M., Nagelkerke, N. & Jha, P. ( 2008; ). Trends in HIV incidence in India from 2000 to 2007. Lancet 372, 289–290.
    [Google Scholar]
  3. Barin, F., Brunet, S., Brand, D., Moog, C., Peyre, R., Damond, F., Charneau, P. & Barre-Sinoussi, F. ( 2004; ). Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J Infect Dis 189, 322–327.[CrossRef]
    [Google Scholar]
  4. Betts, M., Krowka, J., Santamaria, C., Balsamo, K., Gao, F., Mulundu, G., Luo, C., N'Gandu, N., Sheppard, H. & other authors ( 1997; ). Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 71, 8908–8911.
    [Google Scholar]
  5. Braibant, M., Brunet, S., Costagliola, D., Rouzioux, C., Agut, H., Katinger, H., Autran, B. & Barin, F. ( 2006; ). Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20, 1923–1930.[CrossRef]
    [Google Scholar]
  6. Brown, B., Wieczorek, L., Sanders-Buell, E., Rosa Borges, A., Robb, M., Birx, D., Michael, N., McCutchan, F. & Polonis, V. ( 2008; ). Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375, 529–538.[CrossRef]
    [Google Scholar]
  7. Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S., Abdool-Karim, S. & Montefiori, D. ( 2002; ). Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76, 2233–2244.[CrossRef]
    [Google Scholar]
  8. Cao, H., Kanki, P., Sankalé, J., Dieng-Sarr, A., Mazzara, G., Kalams, S., Korber, B., Mboup, S. & Walker, B. ( 1997; ). Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol 71, 8615–8623.
    [Google Scholar]
  9. Cavacini, L., Duval, M., Patil, A., Wood, C., Mayer, K., Ruprecht, R. & Posner, M. ( 2005; ). Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: implications for active and passive immunotherapy. J Med Virol 76, 146–152.[CrossRef]
    [Google Scholar]
  10. Corti, D., Langedijk, J., Hinz, A., Seaman, M., Vanzetta, F., Fernandez-Rodriguez, B., Silacci, C., Pinna, D., Jarrossay, D. & other authors ( 2010; ). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805.[CrossRef]
    [Google Scholar]
  11. Doria-Rose, N., Klein, R., Manion, M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C., Migueles, S., Wrammert, J. & other authors ( 2009; ). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83, 188–199.[CrossRef]
    [Google Scholar]
  12. Ferrari, G., Humphrey, W., McElrath, M., Excler, J., Duliege, A., Clements, M., Corey, L., Bolognesi, D. & Weinhold, K. ( 1997; ). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396–1401.[CrossRef]
    [Google Scholar]
  13. Health Protection Agency Centre for Infections, Health Protection Scotland and UCL Institute of Child Health ( 2010; ). New HIV diagnoses in the UK by prevention group and estimated world region of infection: 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1252660014023.
  14. Howard, T. & Rasheed, S. ( 1996; ). Genomic structure and nucleotide sequence analysis of a new HIV type 1 subtype A strain from Nigeria. AIDS Res Hum Retroviruses 12, 1413–1425.[CrossRef]
    [Google Scholar]
  15. Koh, W., Forsman, A., Hué, S., van der Velden, G., Yirrell, D., McKnight, A., Weiss, R. & Aasa-Chapman, M. ( 2010; ). Novel subtype C HIV-1 envelopes cloned directly from plasma: coreceptor usage and neutralisation phenotypes. J Gen Virol 91, 2374–2380.[CrossRef]
    [Google Scholar]
  16. Kostrikis, L., Cao, Y., Ngai, H., Moore, J. & Ho, D. ( 1996; ). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 70, 445–458.
    [Google Scholar]
  17. Li, M., Gao, F., Mascola, J., Stamatatos, L., Polonis, V., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors ( 2005; ). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108–10125.[CrossRef]
    [Google Scholar]
  18. Li, B., Decker, J., Johnson, R., Bibollet-Ruche, F., Wei, X., Mulenga, J., Allen, S., Hunter, E., Hahn, B. & other authors ( 2006a; ). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80, 5211–5218.[CrossRef]
    [Google Scholar]
  19. Li, M., Salazar-Gonzalez, J., Derdeyn, C., Morris, L., Williamson, C., Robinson, J., Decker, J., Li, Y., Salazar, M. & other authors ( 2006b; ). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80, 11776–11790.[CrossRef]
    [Google Scholar]
  20. Louisirirotchanakul, S., Beddows, S., Cheingsong-Popov, R., Shaffer, N., Mastro, T., Auewarakul, P., Likanonsakul, S., Wasi, C. & Weber, J. ( 1998; ). Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol 19, 315–320.[CrossRef]
    [Google Scholar]
  21. Lynch, R., Shen, T., Gnanakaran, S. & Derdeyn, C. ( 2009; ). Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses 25, 237–248.[CrossRef]
    [Google Scholar]
  22. Mascola, J., Louder, M., Surman, S., Vancott, T., Yu, X., Bradac, J., Porter, K., Nelson, K., Girard, M. & other authors ( 1996; ). Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12, 1319–1328.[CrossRef]
    [Google Scholar]
  23. Matthews, T., Langlois, A., Robey, W., Chang, N., Gallo, R., Fischinger, P. & Bolognesi, D. ( 1986; ). Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A 83, 9709–9713.[CrossRef]
    [Google Scholar]
  24. McKnight, A., Clapham, P., Goudsmit, J., Cheingsong-Popov, R., Weber, J. & Weiss, R. ( 1992; ). Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 6, 799–802.[CrossRef]
    [Google Scholar]
  25. Moore, J., Cao, Y., Ho, D. & Koup, R. ( 1994; ). Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68, 5142–5155.
    [Google Scholar]
  26. Moore, J., Cao, Y., Leu, J., Qin, L., Korber, B. & Ho, D. ( 1996; ). Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 70, 427–444.
    [Google Scholar]
  27. Nabel, G. ( 2002; ). HIV vaccine strategies. Vaccine 20, 1945–1947.[CrossRef]
    [Google Scholar]
  28. Nyambi, P., Nkengasong, J., Lewi, P., Andries, K., Janssens, W., Fransen, K., Heyndrickx, L., Piot, P. & van der Groen, G. ( 1996; ). Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 70, 6235–6243.
    [Google Scholar]
  29. Patel, M., Hoffman, N. & Swanstrom, R. ( 2008; ). Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 82, 903–916.[CrossRef]
    [Google Scholar]
  30. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. & other authors ( 2009; ). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361, 2209–2220.[CrossRef]
    [Google Scholar]
  31. Richman, D., Wrin, T., Little, S. & Petropoulos, C. ( 2003; ). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144–4149.[CrossRef]
    [Google Scholar]
  32. Samleerat, T., Braibant, M., Jourdain, G., Moreau, A., Ngo-Giang-Huong, N., Leechanachai, P., Hemvuttiphan, J., Hinjiranandana, T., Changchit, T. & other authors ( 2008; ). Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis 198, 868–876.[CrossRef]
    [Google Scholar]
  33. Samleerat, T., Thenin, S., Jourdain, G., Ngo-Giang-Huong, N., Moreau, A., Leechanachai, P., Ithisuknanth, J., Pagdi, K., Wannarit, P. & other authors ( 2009; ). Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387, 388–394.[CrossRef]
    [Google Scholar]
  34. Sather, D., Armann, J., Ching, L., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S. & other authors ( 2009; ). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83, 757–769.[CrossRef]
    [Google Scholar]
  35. Seaman, M., Janes, H., Hawkins, N., Grandpre, L., Devoy, C., Giri, A., Coffey, R., Harris, L., Wood, B. & other authors ( 2010; ). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84, 1439–1452.[CrossRef]
    [Google Scholar]
  36. Shankarappa, R., Margolick, J., Gange, S., Rodrigo, A., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C., Learn, G. & other authors ( 1999; ). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73, 10489–10502.
    [Google Scholar]
  37. Spira, S., Wainberg, M., Loemba, H., Turner, D. & Brenner, B. ( 2003; ). Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51, 229–240.[CrossRef]
    [Google Scholar]
  38. Tomaras, G., Yates, N., Liu, P., Qin, L., Fouda, G., Chavez, L., Decamp, A., Parks, R., Ashley, V. & other authors ( 2008; ). Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82, 12449–12463.[CrossRef]
    [Google Scholar]
  39. Weber, J., Fenyö, E., Beddows, S., Kaleebu, P. & Björndal, A. ( 1996; ). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 70, 7827–7832.
    [Google Scholar]
  40. Wei, X., Decker, J., Wang, S., Hui, H., Kappes, J., Wu, X., Salazar-Gonzalez, J., Salazar, M., Kilby, J. & other authors ( 2003; ). Antibody neutralization and escape by HIV-1. Nature 422, 307–312.[CrossRef]
    [Google Scholar]
  41. Weiss, R., Clapham, P., Weber, J., Dalgleish, A., Lasky, L. & Berman, P. ( 1986; ). Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324, 572–575.[CrossRef]
    [Google Scholar]
  42. Zheng, N. & Daniels, R. ( 2001; ). Maintenance of glycoprotein-determined phenotype in an HIV type 1 (pNL43) env gene-cassetting system. AIDS Res Hum Retroviruses 17, 1501–1506.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.024224-0
Loading
/content/journal/jgv/10.1099/vir.0.024224-0
Loading

Data & Media loading...

Supplements

vol. , part 11, pp. 2794 - 2803

Details of additional C and B viruses used as a separate virus panel for neutralization tests [PDF](53 KB)



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error